KOD News and Press, Kodiak Sciences Inc From 02/09/23

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting PR Newswire PALO ALTO, Calif. , Feb. 9, 2023 ...

Summary The stock of Kodiak Sciences was crushed last February when its lead developmental asset failed to meet its primary end point in much anticipated study. However, the stock now sells for less than net cash on its balance sheet and will have readouts from four other trials this ye...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire PALO ALTO, Calif. , Jan. 4, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing t...

Summary I've conducted a study of dozens of different value ratios. I outline my method here and present my results. I discuss value ratios in general, outlining what periods you should use and explaining why some ratios use price and others use enterprise value. The most effective ...

Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference PR Newswire PALO ALTO, Calif. , Nov. 16, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and com...

Summary Primary endpoint of phase 3 BEACON study, using tarcocimab tedromer for the treatment of patients with macular edema due to retinal vein occlusion, was met. Four additional studies are expected to have data releases in 2023; GLEAM/GLIMMER/DAYLIGHT/GLOW. Kodiak will onl...

Kodiak Sciences press release ( NASDAQ: KOD ): Q3 GAAP EPS of -$1.47 beats by $0.31 . Kodiak ended the third quarter of 2022 with $537.4 million of cash, cash equivalents and marketable securities. For further details see: Kodiak Sciences GAAP EPS of -$1.47 b...

Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , Nov. 9, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing...

The following slide deck was published by Kodiak Sciences Inc. in conjunction with this event. For further details see: Kodiak Sciences (KOD) Presents at the 22nd Euretina Congress - Slideshow